We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

PerkinElmer Partners with Cerep for Custom Drug Discovery Solutions

PerkinElmer Partners with Cerep for Custom Drug Discovery Solutions

PerkinElmer Partners with Cerep for Custom Drug Discovery Solutions

PerkinElmer Partners with Cerep for Custom Drug Discovery Solutions

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PerkinElmer Partners with Cerep for Custom Drug Discovery Solutions"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PerkinElmer, Inc. and Cerep SA have announced the signing of a supply and co-marketing agreement to deliver custom drug discovery services.

Under the terms of the agreement, PerkinElmer will exclusively market Cerep’s target screening and profiling services to its customers, and the companies will jointly promote PerkinElmer’s assay technologies and Cerep services to the drug discovery market.

“This agreement represents the latest step in our strategy to build the most comprehensive offering in biochemical and cellular screening for drug discovery,” said Robert F. Friel, president and chief executive officer, PerkinElmer, Inc.

“Our customers will benefit from direct access to Cerep’s expertise in high throughput screening and profiling services, while PerkinElmer will be able to extend the reach of our leading assay technologies and assay development services into key drug discovery markets.”

“Cerep is committed to providing the highest quality services in drug discovery and drug development and we are pleased to work with an established leader of drug discovery technologies to further strengthen our offerings,” said Thierry Jean, chairman and chief executive officer, Cerep. “This agreement with PerkinElmer enables us to support our customers’ complete drug discovery needs, from assay design to target screening and profiling, by adding a range of enabling assay technologies to our drug screening and profiling services.”

This agreement provides PerkinElmer customers with an option to work with a single vendor throughout the entire drug discovery process. Cerep customers will now have access to several key assay development and detection platforms from PerkinElmer’s Bio-discovery business, including AlphaScreen®, AlphaLISA™, LANCE®, and LANCE® Ultra™ for G protein-coupled receptor (GPCR) and kinase assay development.